UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044529
Receipt number R000050854
Scientific Title Observational prospective study to evaluate clinical significance of statin therapy for secondary prevention in hemodialysis patients
Date of disclosure of the study information 2021/06/20
Last modified on 2022/04/02 12:14:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational prospective study to evaluate clinical significance of statin therapy for secondary prevention in hemodialysis patients

Acronym

Prospective study of statin therapy in HD patients

Scientific Title

Observational prospective study to evaluate clinical significance of statin therapy for secondary prevention in hemodialysis patients

Scientific Title:Acronym

Prospective study of statin therapy in HD patients

Region

Japan


Condition

Condition

Coronary artery disease

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study was to investigate the effectiveness of statin therapy for secondary prevention of cardiovascular disease in patients on hemodialysis

Basic objectives2

Others

Basic objectives -Others

Identify clinical factors affecting statin treatment effectiveness for secondary prevention using stratified analysis

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The following outcomes during 3 years after discharge.

1. All cause mortality
2. Non-fatal myocardial infarction

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

The study patients, who admitted to study facility, met all of the following inclusion criteria;

1. Patients on hemodialysis

Key exclusion criteria

The study patients met any of the following exclusion criteria were excluded:

1. Unsuccessful percutaneous coronary intervention
2. Died within 30 days after percutaneous coronary intervention

Target sample size

350


Research contact person

Name of lead principal investigator

1st name Takeo
Middle name
Last name Horikoshi

Organization

Yamanashi University Hospital

Division name

Internal Medicine II

Zip code

409-3898

Address

1110 Shimokato, Chuo city, Yamanashi Prefecture

TEL

055-273-9590

Email

thorikoshi@yamanashi.ac.jp


Public contact

Name of contact person

1st name Takeo
Middle name
Last name Horikoshi

Organization

Yamanashi University Hospital

Division name

Internal Medicine II

Zip code

409-3898

Address

1110 Shimokato, Chuo city, Yamanashi Prefecture

TEL

055-273-9590

Homepage URL


Email

thorikoshi@yamanashi.ac.jp


Sponsor or person

Institute

University of Yamanashi, Department of Internal Medicine II

Institute

Department

Personal name



Funding Source

Organization

University of Yamanashi, Department of Internal Medicine II

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yamanashi University Hospital

Address

1110 Shimokato, Chuo City, Yamanashi Prefecture

Tel

0552739590

Email

kugiyama@yamanashi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

市立藤枝総合病院(静岡県)
山梨県立中央病院(山梨県)
市立甲府病院(山梨県)
甲府城南病院(山梨県)
山梨厚生病院(山梨県)


Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 20 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

323

Results

MACE occurred in 55 patients. Patients with MACE had significantly lower statin therapy. Multivariable Cox proportional hazards analysis showed that the patients on statins had significantly reduced rate of MACE occurrence.

Results date posted

2022 Year 04 Month 02 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2021 Year 10 Month 06 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 04 Month 01 Day

Date of IRB

2007 Year 10 Month 01 Day

Anticipated trial start date

2008 Year 05 Month 01 Day

Last follow-up date

2021 Year 12 Month 01 Day

Date of closure to data entry

2021 Year 12 Month 31 Day

Date trial data considered complete

2021 Year 12 Month 31 Day

Date analysis concluded

2021 Year 12 Month 31 Day


Other

Other related information

All registered patients were prospectively followed up every 6 months in the hospital or with a clinic visit for a period of up to 3 years.


Management information

Registered date

2021 Year 06 Month 14 Day

Last modified on

2022 Year 04 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050854


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name